早期使用nootkatone治疗可以防止压力过载引起的心室重塑和心力衰竭
Zhongyuan Liu1,2, Zixin Zhou1, Wenjing Yuan1
1Department of Cardiology, Children's Hospital of Chongqing Medical University, Chongqing, China.
Frontiers in pharmacology
|February 13, 2026
概括
在小鼠模型中,诺卡 (NKT) 在预防和逆转心力衰竭 (HF) 进展方面表现有前途. 早期NKT治疗通过抑制TGF-β1 / Smad3通路改善了心脏功能并减少了纤维化.
科学领域:
- 心血管研究研究心血管研究
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 心力衰竭 (HF) 是一个重要的全球健康负担,代表了心血管疾病的末期阶段.
- 腹腔大动脉收缩 (AAC) 是研究HF进展的验证小鼠模型.
- 鉴定HF的新型治疗剂至关重要.
研究的目的:
- 在AAC诱导的HF小鼠模型中研究nootkatone (NKT) 的治疗潜力.
- 评估NKT对心脏功能,结构和纤维化通路的影响.
主要方法:
- 在小鼠中使用腹腔大动脉收缩 (AAC) 诱导HF.
- 诺卡 (NKT) 给药开始于AAC后8天,持续8周.
- 评估心脏功能 (排泄分数,分数缩短),心脏结构和分子标记 (尿酸,原蛋白,TGF-β1 / Smad3通路).
主要成果:
- 在AAC小鼠中,早期NKT治疗可以预防心脏功能障碍和结构变化 (例如,左心室质量减少,心肌细胞区域减少).
- NKT显著降低了心房 natriuretic (ANP),大脑 natriuretic (BNP), I 和 III 类型的原体和 TGF-β1 信号元件的表达.
- NKT降低了心脏纤维细胞激活和心肌纤维化,可能是通过抑制TGF-β1 / Smad3通路.
结论:
- 在AAC小鼠模型中,诺卡 (NKT) 证明了延迟或逆转心力衰竭进展的有效性.
- NKT可以减轻心脏缩和纤维化,这表明它具有保护作用.
- 通过抑制TGF-β1/Smad3信号通路,NKT的治疗效果可能会受到介导.
相关概念视频
01:29Heart Failure II: Pathophysiology
1.0K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.0K
01:17Pathophysiology of Heart Failure
4.0K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.0K
01:27Heart Failure I: Introduction
958
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
958
01:22Heart Failure VI: Adjunct Therapies
399
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
399
01:22Heart Failure Drugs: Diuretics
1.0K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.0K
01:30Heart Failure V: Medical Management
363
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
363